SG11202004403QA - N4-hydroxycytidine and derivatives and anti-viral uses related thereto - Google Patents

N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Info

Publication number
SG11202004403QA
SG11202004403QA SG11202004403QA SG11202004403QA SG11202004403QA SG 11202004403Q A SG11202004403Q A SG 11202004403QA SG 11202004403Q A SG11202004403Q A SG 11202004403QA SG 11202004403Q A SG11202004403Q A SG 11202004403QA SG 11202004403Q A SG11202004403Q A SG 11202004403QA
Authority
SG
Singapore
Prior art keywords
hydroxycytidine
derivatives
uses related
viral uses
viral
Prior art date
Application number
SG11202004403QA
Other languages
English (en)
Inventor
George Painter
Gregory Bluemling
Michael Natchus
David Guthrie
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of SG11202004403QA publication Critical patent/SG11202004403QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11202004403QA 2017-12-07 2018-12-07 N4-hydroxycytidine and derivatives and anti-viral uses related thereto SG11202004403QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762595907P 2017-12-07 2017-12-07
US201862626998P 2018-02-06 2018-02-06
US201862760434P 2018-11-13 2018-11-13
PCT/US2018/064503 WO2019113462A1 (en) 2017-12-07 2018-12-07 N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Publications (1)

Publication Number Publication Date
SG11202004403QA true SG11202004403QA (en) 2020-06-29

Family

ID=66751806

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004403QA SG11202004403QA (en) 2017-12-07 2018-12-07 N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Country Status (17)

Country Link
US (3) US11331331B2 (de)
EP (1) EP3706762B1 (de)
JP (4) JP6804790B1 (de)
KR (3) KR102248165B1 (de)
CN (2) CN111372592A (de)
AU (2) AU2018378832B9 (de)
BR (2) BR122022008466B1 (de)
CA (1) CA3082191C (de)
GB (2) GB2590198B (de)
IL (2) IL274155B (de)
MX (2) MX2020005392A (de)
PH (1) PH12020550607A1 (de)
RU (1) RU2020116571A (de)
SA (1) SA520412305B1 (de)
SG (1) SG11202004403QA (de)
WO (1) WO2019113462A1 (de)
ZA (1) ZA202002849B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211456T1 (hr) * 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
KR102248165B1 (ko) * 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN112390838A (zh) * 2019-08-14 2021-02-23 斯微(上海)生物科技有限公司 一种改性核苷及其合成方法
AU2020346908A1 (en) * 2019-09-11 2022-03-24 The Scripps Research Institute Antiviral prodrugs and formulations thereof
CA3167054A1 (en) * 2020-02-07 2021-08-12 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN111285911B (zh) * 2020-02-26 2021-04-02 山东大学 Gem-1mt两亲小分子化合物及其制剂、制备方法和应用
WO2021183750A2 (en) 2020-03-12 2021-09-16 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
JP2023522245A (ja) 2020-04-21 2023-05-29 イミュニック アクチェンゲゼルシャフト ウイルス性疾患の治療又は予防において使用するためのビドフルジムス
US12097212B2 (en) 2020-06-08 2024-09-24 Brigham Young University Use of cationic steroidal antimicrobial compounds to deactivate coronavirus
CA3191082A1 (en) * 2020-08-27 2022-03-03 Jameson R. BOTHE Novel forms of antiviral nucleosides
US11702440B2 (en) * 2020-12-10 2023-07-18 Optimus Drugs Private Limited Pharmaceutical polymorphs of Molnupiravir
EP4262816A4 (de) * 2020-12-18 2024-05-15 Merck Sharp & Dohme LLC Herstellung antiviraler nukleoside
CN112608357B (zh) * 2020-12-21 2022-12-09 杭州科巢生物科技有限公司 一种抗病毒药物Molnupiravir的制备方法
CN112778387A (zh) * 2021-01-15 2021-05-11 杭州科巢生物科技有限公司 一种Molnupiravir晶型A及其制备方法
WO2022168106A1 (en) * 2021-02-06 2022-08-11 Fermenta Biotech Limited Chemo-enzymatic process for synthesis of molnupiravir
WO2022168107A1 (en) * 2021-02-06 2022-08-11 Fermenta Biotech Limited Enzymatic synthesis of molnupiravir intermediate
CN112552288A (zh) * 2021-02-19 2021-03-26 南京桦冠生物技术有限公司 一种4-肟-5`-（2-甲基丙酰基）尿苷的制备方法
CN113072606A (zh) * 2021-03-18 2021-07-06 南京正济医药研究有限公司 一种n4-羟基胞苷类化合物的晶型及其制备方法与用途
US11312743B1 (en) * 2021-03-20 2022-04-26 Optimus Drugs Private Limited Process for molnupiravir
WO2022208156A1 (en) * 2021-03-29 2022-10-06 Optimus Pharma Private Limited Pharmaceutical composition of molnupiravir
KR20240007144A (ko) 2021-04-09 2024-01-16 이뮤닉 아게 중수소화 dhodh 억제제
CN115215914B (zh) * 2021-04-15 2024-05-28 中国科学院上海药物研究所 核苷类似物及其用途
US11407779B1 (en) 2021-04-23 2022-08-09 Divi's Laboratories Ltd. Process for the preparation of molnupiravir
CN113307834A (zh) * 2021-04-23 2021-08-27 安徽贝克联合制药有限公司 一种核糖核苷类似物的多晶型物、其制备方法及应用
CN113278040B (zh) * 2021-06-16 2022-07-05 苏州立新制药有限公司 5’-异丁酰基-n4-羟基胞苷的制备方法
CN117642410A (zh) * 2021-06-18 2024-03-01 苏州春海生物医药有限公司 N4-羟基胞苷的酯衍生物及其用途
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途
CN113433242B (zh) * 2021-06-28 2022-12-27 成都大学 Molnupiravir含量及有关物质的检测方法
CN113278041B (zh) * 2021-07-16 2021-10-19 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
BR112024002195A2 (pt) 2021-08-06 2024-04-30 Intervet Int Bv USOS DE UM NUCLEOSÍDEO ANTIVIRAL ß-d-N(4)-HIDROXICITIDINA PARA PREVENIR OU TRATAR UMA DOENÇA VIRAL OU PARA INDUZIR UMA RESPOSTA ANTIVIRAL EM UM ANIMAL
CN115960148B (zh) * 2021-08-27 2023-12-12 南京知和医药科技有限公司 一种新型的胞苷衍生物及其药物组合物和用途
WO2023068287A1 (ja) * 2021-10-19 2023-04-27 興和株式会社 新規医薬
WO2023067623A1 (en) * 2021-10-20 2023-04-27 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) A short and cost effective synthetic route towards anti viral eidd-1931 and its hydrate polymorphs
CN114085259A (zh) * 2021-10-21 2022-02-25 苏州立新制药有限公司 N4-羟基胞苷一水合物及其晶型b与制备方法和用途
CN113880902A (zh) * 2021-10-26 2022-01-04 江苏睿实生物科技有限公司 一种Molnupiravir药物中间体及其制备方法
TW202333706A (zh) 2021-11-01 2023-09-01 德商埃慕尼克股份公司 Ｎ—羥基胞磷膽鹼（ｃｉｔｉｃｏｌｉｎｅ）化合物的醫藥用途
CN113929724B (zh) * 2021-11-02 2024-05-31 周雨恬 一种核苷类化合物及其药物组合物和用途
CN114306254B (zh) * 2021-11-30 2023-11-03 南京正济医药研究有限公司 一种Molnupiravir口服固体制剂及其制备方法
CN116217632A (zh) * 2021-12-06 2023-06-06 广州谷森制药有限公司 一种氘代胞苷衍生物的制备方法
WO2023111683A1 (en) * 2021-12-16 2023-06-22 Ascletis Bioscience Co., Ltd. N4-hydroxycytidine derivatives and use thereof as antiviral agent
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
WO2023118896A1 (en) 2021-12-23 2023-06-29 Subintro Limited Novel antiviral compositions comprising oleic acid
CA3240950A1 (en) 2021-12-23 2023-06-29 Christian Gege Dhodh inhibitors containing a carboxylic acid bioisostere
CN114507266A (zh) * 2022-01-24 2022-05-17 海门品尚医药科技有限公司 一种Molnupiravir晶型及其制备方法
CN114560894B (zh) * 2022-03-11 2023-06-20 浙江乐普药业股份有限公司 一种抗新冠药物Molnupiravir的制备方法
CN114773405B (zh) * 2022-06-21 2022-09-23 和鼎（南京）医药技术有限公司 一种莫那比拉韦的制备方法
WO2024125604A1 (en) * 2022-12-16 2024-06-20 Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. Diester derivatives of n4-hydroxycytidine and use thereof
WO2024129551A1 (en) * 2022-12-16 2024-06-20 Merck Sharp & Dohme Llc Solid dosage form of a small molecule antiviral and uses thereof
WO2024144420A1 (ru) * 2022-12-28 2024-07-04 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Применение 5'-о-(3-фенилпропионил)-n4-гидроксицитидина для ингибирования репликации вируса гриппа in vitro и in vivo

Family Cites Families (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1325797A (en) 1970-09-24 1973-08-08 Upjohn Co Medicines comprising cytidine derivatives
GB1386334A (en) 1972-09-22 1975-03-05 Kohjin Co 2,2-cyclocytidine derivatives
FR2252851B1 (de) 1973-11-29 1978-07-21 Kohjin Co
US4096324A (en) 1975-07-07 1978-06-20 The Upjohn Company Cytidine nucleoside compound
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
CA2058632C (en) 1989-06-05 2004-08-24 Brian C. Froehler Exonuclease-resistant oligonucleotides and methods for preparing the same
AU9094991A (en) 1990-11-23 1992-06-25 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
FI105556B (fi) 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta
CZ287745B6 (cs) 1991-10-11 2001-01-17 Ústav organické chemie a biochemie AV ČR Acyklické fosfonomethoxyalkylsubstituované alkenylové a alkinylové deriváty purinu a pyrimidinu
EP0637965B1 (de) 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
EP0695306A1 (de) 1993-04-19 1996-02-07 Gilead Sciences, Inc. Erhoehte bildung von tripel-und doppel-helix mit modifizierte purine enthaltenden oligomeren
US5349947A (en) 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
JPH09506333A (ja) 1993-09-17 1997-06-24 ギリアード サイエンシーズ，インコーポレイテッド 治療化合物の投薬方法
WO1995007920A1 (en) 1993-09-17 1995-03-23 Gilead Sciences, Inc. Nucleotide analogs
BR9607098B8 (pt) 1995-02-27 2014-11-18 Gilead Sciences Inc Composto e composição farmacêutica.
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
CA2268756A1 (en) 1996-10-21 1998-04-30 Gilead Sciences, Inc. Piperidine compounds
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
EP2180064A3 (de) 2000-10-18 2010-08-11 Pharmasset, Inc. Multiplex Quantifizierung von Nukleinsäuren in erkrankten Zellen
CA2743451A1 (en) * 2000-10-18 2002-04-25 Pharmasset, Inc. Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
SK287423B6 (sk) 2001-04-30 2010-09-07 Trommsdorff Gmbh & Co. Kg Arzneimittel Farmaceuticky účinné uridínové estery, ich použitie, spôsob ich prípravy a farmaceutický prostriedok
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
AU2003231766A1 (en) 2002-04-26 2003-11-10 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
ES2381266T3 (es) 2002-07-15 2012-05-24 Gilead Sciences, Inc. Terapias de combinación de L-FMAU para el tratamiento de la infección por el virus de la hepatitis B
EP1950563A3 (de) 2002-09-11 2008-08-06 Michio Ishibashi Verfahren zum Screenen einer Substanz zur Förderung der Regeneration von Makrophagen
EP1546190A2 (de) 2002-10-01 2005-06-29 Gilead Sciences, Inc. Hbv veränderungen verbunden mit verringerter anfälligkeit gegenüber adefovir
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20040171860A1 (en) 2002-11-12 2004-09-02 Hong Zhao Novel acylating reagents
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
AU2003297612A1 (en) 2002-12-02 2004-06-23 Gilead Sciences, Inc. 2-substituted-3-propenamide derivatives and methods of using the same
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2004100960A2 (en) 2003-04-25 2004-11-25 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
EP1628685B1 (de) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antivirale phosphonate analoge
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US20060252729A1 (en) 2003-07-30 2006-11-09 Krawczyk Steven H Nucleobase phosphonate analogs for antiviral treatment
CA2537325A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
RU2264409C2 (ru) 2003-10-01 2005-11-20 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") 2`-амино-2`-дезоксинуклеозиды - ингибиторы репродукции вирусов кори и марбург
AU2004290298A1 (en) 2003-10-24 2005-05-26 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US20070160554A1 (en) 2003-11-03 2007-07-12 Cognis Ip Management Gmbh Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same
AU2004309390B2 (en) 2003-12-22 2011-06-02 Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
BRPI0417988A (pt) 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
NZ548771A (en) 2003-12-30 2010-05-28 Gilead Sciences Inc Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
CN1934093A (zh) 2004-01-12 2007-03-21 吉里德科学公司 嘧啶基膦酸酯抗病毒化合物和使用方法
US20070281911A1 (en) 2004-01-21 2007-12-06 Gilead Sciences Inc. Use of Adefovir or Tenofovir for Inhibiting Mmtv-Like Viruses Involved in Breast Cancer and Primary Biliary Cirrhosis
AU2005249363A1 (en) 2004-04-14 2005-12-15 Zhenhong R. Cai Phosphonate analogs of HIV integrase inhibitor compounds
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
KR20070034119A (ko) 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
ME03423B (de) 2004-07-27 2020-01-20 Gilead Sciences Inc Phosphonat Analoga von HIV Inhibitor Verbindungen
KR101238430B1 (ko) 2004-07-27 2013-02-28 길리애드 사이언시즈, 인코포레이티드 이미다조［4,5-ｄ］피리미딘, 그들의 용도 및 제조방법
DE102004051804A1 (de) * 2004-10-21 2006-04-27 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen
JP2008518024A (ja) 2004-10-26 2008-05-29 ギリアード サイエンシーズ， インコーポレイテッド ミコフェノール酸のホスホネート誘導体
JP2008524335A (ja) 2004-12-21 2008-07-10 ギリアド サイエンシズ， インコーポレイテッド イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス処置法
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
EP1893192A4 (de) 2005-06-08 2010-03-31 Univ North Carolina Verfahren zur ermöglichung des überlebens von nervenzellen anhand nicht-peptidischer und peptidscher bdnf-neurotrophin-mimetika
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
WO2007014174A2 (en) 2005-07-25 2007-02-01 Gilead Sciences, Inc. Drug-resistant mutants of hepatitis c virus
CA2616314A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
KR20080035698A (ko) 2005-08-16 2008-04-23 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
CN101268092B (zh) 2005-09-22 2012-07-04 弗·哈夫曼-拉罗切有限公司 核苷的选择性o-酰基化
SG170796A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Us Methods for improving the pharmacokinetics of hiv integrase inhibitors
SI1999133T1 (sl) 2006-03-29 2013-10-30 Gilead Sciences, Inc. Postopek za pripravo HIV proteaznih inhibitorjev
US20090318456A1 (en) 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
AU2007269557B2 (en) 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
ES2339298T3 (es) 2006-07-07 2010-05-18 Gilead Sciences, Inc. Compuesto de piridazina novedoso y uso del mismo.
KR101636221B1 (ko) 2006-07-07 2016-07-04 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
WO2008011117A2 (en) 2006-07-21 2008-01-24 Gilead Sciences, Inc. Antiviral protease inhibitors
CA2657821A1 (en) 2006-07-21 2008-01-24 Gilead Sciences, Inc. Aza-peptide protease inhibitors
EP2069356A1 (de) 2006-07-24 2009-06-17 Gilead Sciences, Inc. Bisfuranylproteasehemmer
MX2009000871A (es) 2006-07-24 2009-05-08 Gilead Sciences Inc Novedosos inhibidores de transcriptasa inversa de vih.
US20100189772A1 (en) 2006-09-27 2010-07-29 Coley Pharmaceutical Group, Inc Compositions of TLR ligands and antivirals
DK2094702T3 (en) 2006-12-14 2015-12-07 Gilead Sciences Inc viral inhibitors
WO2008077650A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8324179B2 (en) 2007-02-09 2012-12-04 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
LT2487162T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
CN101668515B (zh) * 2007-03-29 2013-03-20 弗·哈夫曼-拉罗切有限公司 药物组合物和方法
JP2010532350A (ja) 2007-06-29 2010-10-07 コレア リサーチ インスティテュート オブ ケミカル テクノロジー 新規のｈｉｖ逆転写酵素阻害剤
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
MX2009013832A (es) 2007-06-29 2010-03-10 Gilead Sciences Inc Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
AP2490A (en) 2007-06-29 2012-10-04 Gilead Sciences Inc Therapeutic compositions and the use thereof
TW200918524A (en) 2007-06-29 2009-05-01 Gilead Sciences Inc Antiviral compounds
EA019749B1 (ru) 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Противовирусные соединения
BRPI0813000A2 (pt) 2007-06-29 2014-12-23 Gilead Sciences Inc Composições terapêuticas e uso das mesmas
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
WO2009058800A2 (en) 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
EP2234623A4 (de) 2007-12-27 2012-03-28 Epiphany Biosciences Antivirale verbindungen
AU2008346823B2 (en) 2008-01-04 2015-03-12 Gilead Sciences, Inc. Inhibitors of cytochrome P450
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
SI2937350T1 (en) 2008-04-23 2018-05-31 Gilead Sciences, Inc. 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT
WO2009143011A1 (en) 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
US8536187B2 (en) 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
AU2009273844A1 (en) 2008-07-25 2010-01-28 Gilead Sciences, Inc. Antiviral compounds
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
CN102300871A (zh) 2008-12-19 2011-12-28 吉里德科学公司 Hcv ns3蛋白酶抑制剂
TW201036612A (en) 2008-12-22 2010-10-16 Gilead Sciences Inc Antiviral compounds
EP2396340B1 (de) 2009-02-10 2013-12-18 Gilead Sciences, Inc. Carbanukleosidanaloga zur antivirusbehandlung
CN109020961A (zh) 2009-05-13 2018-12-18 吉利德制药有限责任公司 抗病毒化合物
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
UY32715A (es) 2009-06-23 2011-01-31 Gilead Sciences Inc Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
UY32721A (es) 2009-06-23 2011-01-31 Gilead Sciences Ltd Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
AR077139A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Composiciones farmaceuticas utiles para tratar el vch
US8999969B2 (en) 2009-07-09 2015-04-07 Gilead Sciences, Inc. Anti-RSV compounds
CN102471327A (zh) 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
AU2010292411B2 (en) 2009-09-09 2015-04-09 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
AU2010292102B2 (en) 2009-09-14 2015-04-09 Gilead Sciences, Inc. Modulators of Toll-like receptors
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
RS55699B1 (sr) 2009-09-21 2017-07-31 Gilead Sciences 2' -fluoro supstituisani karba-nukleozidni analozi zaantiviralno lečenje
CN102666541B (zh) 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
AP2012006413A0 (en) 2010-01-15 2012-08-31 Gilead Sciences Inc Inhibitors of flaviviridae viruses
TWI491609B (zh) 2010-01-15 2015-07-11 Gilead Sciences Inc 黃熱病毒科（Ｆｌａｖｉｖｉｒｉｄａｅ）病毒之抑制劑類
PL2528930T3 (pl) * 2010-01-28 2014-03-31 Riboscience Llc 4`-azydonukleozydy jako związki przeciw hcv
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
CA2796826A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
EP2571882A1 (de) 2010-05-21 2013-03-27 Gilead Sciences, Inc. Hetercyclische flaviviridae-virenhemmer
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US20110306541A1 (en) 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
AU2011264952B2 (en) 2010-06-11 2014-08-14 Quarraisha Abdool Karim Topical antiviral formulations for prevention of transmission of HSV-2
EP2585467B1 (de) 2010-06-24 2016-03-02 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidine und -triazine als antivirale agentien
TWI458711B (zh) 2010-07-02 2014-11-01 Gilead Sciences Inc 治療性化合物
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
EP2805960A1 (de) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Verfahren für die Zubereitung von diasteromerenreinen Phosphoramidat-Prodrugs
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
CN102351931B (zh) 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
CA2807496C (en) 2010-09-20 2019-01-22 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ726475A (en) 2010-11-17 2018-07-27 Gilead Pharmasset Llc Antiviral compounds
CN106511357A (zh) 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
NZ613370A (en) 2010-12-20 2015-05-29 Gilead Sciences Inc Combinations for treating hcv
WO2012088153A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
US20130274254A1 (en) 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
WO2012088156A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2012138669A1 (en) 2011-04-04 2012-10-11 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
CA2830838A1 (en) 2011-04-04 2012-11-10 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
WO2012151165A1 (en) 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN103687868A (zh) 2011-07-06 2014-03-26 吉利德科学股份有限公司 Hcv基因型4复制子
US8889848B2 (en) 2011-07-06 2014-11-18 Gilead Sciences, Inc. HCV genotype 3 replicons
AU2012280959B2 (en) 2011-07-13 2015-08-06 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of Flaviviridae viruses
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
WO2013066748A1 (en) 2011-10-31 2013-05-10 Gilead Pharmasset Llc Methods and compositions for treating hepatitis c virus
EP2635588B1 (de) 2011-11-16 2015-06-10 Gilead Pharmasset LLC Kondensierte imidazolylimidazole als antivirale verbindungen
JP5899327B2 (ja) 2011-11-29 2016-04-06 ギリアド ファーマセット エルエルシー Ｃ型肝炎ウイルスを処置するための組成物および方法
WO2013090840A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
WO2013090929A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
EP2793891A1 (de) 2011-12-20 2014-10-29 Gilead Sciences, Inc. Pharmazeutische zusammensetzungen und verfahren zur behandlung von magen-darm-infektionen und -störungen
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6122868B2 (ja) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
CA2860995A1 (en) 2012-01-12 2013-07-18 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
EA026138B1 (ru) 2012-02-03 2017-03-31 Джилид Сайэнс, Инк. Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
EA201791916A1 (ru) 2012-03-13 2018-07-31 Джилид Сайэнс, Инк. 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
GEP201706721B (en) 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
NZ701647A (en) 2012-04-17 2016-05-27 Gilead Sciences Inc Compounds and methods for antiviral treatment
SG11201401189WA (en) 2012-04-20 2014-09-26 Gilead Sciences Inc Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
MX2014014768A (es) 2012-06-08 2015-05-11 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae.
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
WO2014055618A1 (en) 2012-10-03 2014-04-10 Gilead Sciences, Inc. Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid)
BR112015008757A2 (pt) 2012-10-26 2017-07-04 Koninklijke Philips Nv dispositivo de exibição e método para operação de um dispositivo de exibição
RU2015119999A (ru) 2012-10-29 2016-12-20 Кокристал Фарма, Инк. Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака
SG10201703240RA (en) 2012-10-30 2017-06-29 Gilead Sciences Inc Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
AU2013341227A1 (en) 2012-11-07 2015-05-07 Gilead Sciences, Inc. HCV genotype 6 replicons
EP2935304A1 (de) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluor-nukleoside zur behandlung von hcv
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
MX357940B (es) 2012-12-21 2018-07-31 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
WO2014100505A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP5941598B2 (ja) 2013-01-09 2016-06-29 ギリアード サイエンシーズ， インコーポレイテッド ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (de) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutische verbindungen zur behandlung von vireninfektionen
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
US20140273023A1 (en) 2013-03-15 2014-09-18 Saladax Biomedical Inc. Gemcitabine immunoassay
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
US20140309164A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating hcv
UA123533C2 (uk) 2013-05-16 2021-04-21 Рібосаєнс Ллс 4'-фтор-2'-метилзаміщені нуклеозидні похідні
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015023893A1 (en) 2013-08-16 2015-02-19 Gilead Sciences, Inc. Hcv genotype 4d replicons
US10149859B2 (en) 2013-09-11 2018-12-11 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015084741A2 (en) 2013-12-02 2015-06-11 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
JP6568541B2 (ja) 2013-12-23 2019-08-28 ギリアド ファーマセット エルエルシー 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態
TW201609785A (zh) 2013-12-23 2016-03-16 吉李德製藥公司 固體型之抗病毒化合物
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
EP3613418A1 (de) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur modulierung von hormonspiegeln
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015179448A1 (en) 2014-05-21 2015-11-26 Gilead Sciences, Inc. Therapeutic compounds
EP3154985B1 (de) 2014-06-12 2018-06-06 Gilead Sciences, Inc. Antivirale verbindungen
JP6383810B2 (ja) 2014-06-13 2018-08-29 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤としてのキナゾリノン誘導体
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
ES2833025T3 (es) 2014-06-13 2021-06-14 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa
WO2015191745A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN106573922A (zh) 2014-06-13 2017-04-19 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JP6669675B2 (ja) 2014-06-24 2020-03-18 ヤンセン バイオファーマ インク． 置換ヌクレオシド、ヌクレオチドおよびその類似体
CA2952966A1 (en) 2014-06-24 2015-12-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN105288635A (zh) 2014-06-26 2016-02-03 昆明积大制药股份有限公司 一种含有阿糖胞苷5’-0-氨基酸酯的药物组合物
CA2954056C (en) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
EP3186239B1 (de) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretrovirale agenzien
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EP3034499A1 (de) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Neuartige FXR (NR1H4) modulierende Verbindungen
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
JP6385584B2 (ja) 2014-12-24 2018-09-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための縮合ピリミジン化合物
MX2017008518A (es) 2014-12-24 2017-10-25 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
HRP20211456T1 (hr) * 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
WO2016134054A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
SI3321265T1 (sl) 2015-03-04 2020-07-31 Gilead Sciences, Inc. Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
EP3736274A1 (de) 2015-04-02 2020-11-11 Gilead Sciences, Inc. Polycyclische carbamoylpyridonverbindungen und deren pharmazeutische verwendung
WO2016168349A1 (en) 2015-04-14 2016-10-20 Gilead Sciences, Inc. Methods of treating hepatitis b virus
CA2985642A1 (en) 2015-05-15 2016-11-24 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
WO2016205141A1 (en) 2015-06-17 2016-12-22 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
EP3607939B1 (de) 2015-06-30 2022-06-01 Gilead Sciences, Inc. Pharmazeutische formulierungen beinhaltend tenofovir und emtricitabine
MX2018001073A (es) 2015-08-06 2018-06-12 Chimerix Inc Nucleosidos de pirrolopirimidina y analogos de los mismos utiles como agentes antivirales.
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017040895A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040896A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
BR112018005048B8 (pt) 2015-09-16 2021-03-23 Gilead Sciences Inc uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
AU2016330895A1 (en) 2015-09-30 2018-05-10 Gilead Sciences, Inc. Compounds and combinations for the treatment of HIV
EP3355875B1 (de) 2015-10-01 2021-09-29 Gilead Sciences, Inc. Kombination aus einem btk-inhibitor und einem checkpoint-inhibitor zur behandlung von krebs
PL3346995T3 (pl) 2015-11-09 2020-03-31 Gilead Sciences, Inc. Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności
MA44077A (fr) 2015-12-15 2021-05-05 Gilead Sciences Inc Anticorps neutralisants le virus de l'immunodéficience humaine
PE20181073A1 (es) 2015-12-17 2018-07-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de union a tank
US10874683B2 (en) 2016-03-10 2020-12-29 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017165489A1 (en) * 2016-03-23 2017-09-28 Emory University Antiviral agents for treating zika and dengue virus infections
PT3377637T (pt) 2016-04-08 2020-06-17 Krystal Biotech Inc Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
US11738013B2 (en) 2016-05-27 2023-08-29 Gilead Sciences, Inc. Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
EP3471738A4 (de) 2016-06-20 2020-01-01 Merck Sharp & Dohme Corp. Cyclische phosphonatsubstituierte nukleosidderivate und verfahren zur verwendung davon zur behandlung von viruserkrankungen
WO2017223268A1 (en) 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
KR102248165B1 (ko) * 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
GB2589205B (en) 2018-03-07 2023-05-24 Univ Emory 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA3167054A1 (en) 2020-02-07 2021-08-12 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Also Published As

Publication number Publication date
IL284100A (en) 2021-07-29
IL274155A (en) 2020-05-31
US20200276219A1 (en) 2020-09-03
MX2020005392A (es) 2020-12-07
SA520412305B1 (ar) 2024-08-07
GB202020498D0 (en) 2021-02-03
KR102248165B1 (ko) 2021-05-06
EP3706762A4 (de) 2021-09-01
JP7305205B2 (ja) 2023-07-10
RU2020116571A (ru) 2021-11-22
PH12020550607A1 (en) 2021-02-15
CA3082191A1 (en) 2019-06-13
CA3082191C (en) 2021-09-21
KR20200071119A (ko) 2020-06-18
EP3706762A1 (de) 2020-09-16
AU2021206866B2 (en) 2024-04-18
AU2018378832B2 (en) 2021-05-20
WO2019113462A1 (en) 2019-06-13
ZA202002849B (en) 2023-01-25
JP2021042235A (ja) 2021-03-18
IL274155B (en) 2021-07-29
GB2581936B (en) 2021-02-10
CN111372592A (zh) 2020-07-03
AU2018378832A1 (en) 2020-05-14
GB2590198B (en) 2022-02-23
JP2021505530A (ja) 2021-02-18
EP3706762B1 (de) 2024-10-16
KR102626210B1 (ko) 2024-01-18
AU2018378832B9 (en) 2021-05-27
JP7179372B2 (ja) 2022-11-29
AU2021206866A1 (en) 2021-08-12
US11903959B2 (en) 2024-02-20
US11331331B2 (en) 2022-05-17
GB2581936A (en) 2020-09-02
GB202008628D0 (en) 2020-07-22
CN118477088A (zh) 2024-08-13
US20220016153A1 (en) 2022-01-20
RU2020116571A3 (de) 2021-11-22
JP2023082213A (ja) 2023-06-13
GB2590198A (en) 2021-06-23
BR122022008466B1 (pt) 2023-12-05
KR20240011880A (ko) 2024-01-26
JP6804790B1 (ja) 2020-12-23
BR112020010581A2 (pt) 2020-11-10
MX2023008882A (es) 2023-08-09
KR20210050594A (ko) 2021-05-07
US20240189335A1 (en) 2024-06-13
JP2021165280A (ja) 2021-10-14

Similar Documents

Publication Publication Date Title
IL284100A (en) N4-Hydroxycytidine and related derivatives and antiviral uses
IL279663A (en) N4-hydroxycytidine, history and related antiviral uses
ZA201808131B (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
HK1246156B (zh) Fgf21衍生物及其用途
IL273571A (en) Azterion derivatives and their uses
IL271290A (en) Dihydro-pyrrolo-pyridine derivatives
IL273839A (en) Benzimidazole derivatives and their uses
EP3526215A4 (de) N-acylethanolamid-derivate und verwendungen davon
GB2577419B (en) Lipo-glycopeptide cleavable derivatives and uses thereof
EP3383401A4 (de) Thienopyrimidinderivate und verwendungen davon
PT3796975T (pt) Derivados de sulfonilaminobenzamida
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
IL275211A (en) Fast and flexible segment chains - division
GB201707279D0 (en) Multiearphones and polyearphones